Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.

Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study. Ann Hematol (2015) 0.78

The application of the palliative prognostic index, charlson comorbidity index, and Glasgow prognostic score in predicting the life expectancy of patients with hematologic malignancies under palliative care. BMC Palliat Care (2015) 0.76

Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leuk Lymphoma (2016) 0.75

The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study. Eur J Clin Pharmacol (2017) 0.75

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood (2007) 5.18

Double-hit B-cell lymphomas. Blood (2010) 3.19

Compliance in heart failure patients: the importance of knowledge and beliefs. Eur Heart J (2005) 2.81

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood (2004) 2.50

Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA (2006) 2.38

Microalbuminuria and risk of venous thromboembolism. JAMA (2009) 2.35

Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. Eur J Heart Fail (2004) 2.30

Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial. Crit Care Med (2010) 2.23

High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation (2007) 2.07

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood (2009) 2.05

Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood (2009) 1.93

High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol (2003) 1.84

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood (2009) 1.84

New-fill injections may induce late-onset foreign body granulomatous reaction. Plast Reconstr Surg (2005) 1.76

Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol (2005) 1.71

Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J (2005) 1.71

Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial. Crit Care Med (2007) 1.71

High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost (2009) 1.64

Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol (2007) 1.64

Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood (2011) 1.63

Compliance with non-pharmacological recommendations and outcome in heart failure patients. Eur Heart J (2010) 1.60

Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation (2012) 1.59

The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. Haematologica (2005) 1.58

Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood (2004) 1.56

Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol (2010) 1.54

Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm (2005) 1.52

Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Arthritis Res Ther (2007) 1.51

Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol (2007) 1.50

Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation (2010) 1.50

Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids. Drugs Aging (2012) 1.46

Evaluation of 1025 fetal deaths: proposed diagnostic workup. Am J Obstet Gynecol (2011) 1.42

Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol (2006) 1.42

Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. Nephrol Dial Transplant (2010) 1.42

Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? Heart Rhythm (2005) 1.42

Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients. Thromb Haemost (2014) 1.40

Thrombogenicity and reoperation of the St. Jude Medical Silzone valve: a comparison with the conventional St. Jude Medical valve. J Heart Valve Dis (2003) 1.38

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica (2008) 1.33

Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol (2004) 1.28

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood (2005) 1.28

The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood (2004) 1.20

Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years. J Endovasc Ther (2007) 1.18

Cytogenetic analysis after evaluation of 750 fetal deaths: proposal for diagnostic workup. Obstet Gynecol (2008) 1.17

Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica (2006) 1.15

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol (2011) 1.13

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol (2008) 1.10

Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol (2014) 1.10

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol (2013) 1.09

Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene (2003) 1.08

Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood (2004) 1.08

High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev (2007) 1.07

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma (2012) 1.07

Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation (2008) 1.07

For better and for worse: Quality of life impaired in HF patients as well as in their partners. Eur J Cardiovasc Nurs (2005) 1.05

Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation (2007) 1.02

High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood (2010) 1.01

Ectomesenchymal chondromyxoid tumor of the anterior tongue. Report of two cases. Oral Oncol (2003) 0.99

Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring. Haematologica (2014) 0.99

An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica (2012) 0.98

Diverse placental pathologies as the main causes of fetal death. Obstet Gynecol (2009) 0.98

Low quality of reporting adverse drug reactions in paediatric randomised controlled trials. Arch Dis Child (2010) 0.97

Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol (2011) 0.97

Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma (2013) 0.95

AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood (2009) 0.94

Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant (2005) 0.94

Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2007) 0.94

Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes. Obes Surg (2013) 0.93

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood (2009) 0.92

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood (2008) 0.92

A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up. J Am Coll Cardiol (2002) 0.92

Criteria for drug selection in frail elderly persons. Drugs Aging (2011) 0.91

Adequate sampling in cryoglobulinaemia: recommended warmly. Clin Chem Lab Med (2003) 0.91

HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation (2005) 0.90

Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol (2007) 0.90

In normal controls, both age and gender affect coagulability as measured by thrombelastography. Anesth Analg (2010) 0.90

Minimally invasive coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty with stenting in isolated high-grade stenosis of the proximal left anterior descending coronary artery: six months' angiographic and clinical follow-up of a prospective randomized study. J Thorac Cardiovasc Surg (2002) 0.89

RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J (2006) 0.89

Isolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? Eur J Cardiothorac Surg (2004) 0.88

Endothelial dysfunction in patients with coronary artery disease: a comparison of three frequently reported tests. J Investig Med (2002) 0.88

Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay. Clin Cancer Res (2007) 0.86

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood (2012) 0.86

The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). Blood (2010) 0.86

Validation of a fully automated HER2 staining kit in breast cancer. Cell Oncol (2010) 0.86

Diurnal variation of ventricular repolarization in a large family with LQT3-Brugada syndrome characterized by nocturnal sudden death. Heart Rhythm (2006) 0.86

Cost-benefit analysis of the detection of prescribing errors by hospital pharmacy staff. Drug Saf (2002) 0.86

Assessing the prognostic value of coronary endothelial function in patients referred for a first coronary angiogram. Am J Cardiol (2004) 0.85

Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol (2005) 0.85

Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med (2007) 0.84